Report cover image

Congenital Hyperinsulinism Treatment Market by Indication Type (Atypical Congenital Hyperinsulinism, Diffuse Congenital Hyperinsulinism, Focal Congenital Hyperinsulinism), Treatment (Dietary Management, Drugs, Surgical Intervention), Route of Administrati

Publisher 360iResearch
Published Apr 17, 2024
Length 192 Pages
SKU # IRE18707419

Description

Congenital Hyperinsulinism Treatment Market by Indication Type (Atypical Congenital Hyperinsulinism, Diffuse Congenital Hyperinsulinism, Focal Congenital Hyperinsulinism), Treatment (Dietary Management, Drugs, Surgical Intervention), Route of Administration, Distribution Channel, End-Users - Global Forecast 2024-2030


The Congenital Hyperinsulinism Treatment Market size was estimated at USD 182.53 million in 2023 and expected to reach USD 192.20 million in 2024, at a CAGR 5.61% to reach USD 267.64 million by 2030.

Congenital hyperinsulinism (CHI) is a complex condition characterized by excessive insulin production in infants and children, leading to severe hypoglycemia. CHI treatment options are multifaceted, aiming to maintain blood glucose levels within a normal range and prevent hypoglycemic episodes. These include medical therapies such as diazoxide, octreotide, and newer drugs like lanreotide, as well as surgical interventions in more severe cases. The major factors contributing to the expansion of CHI treatment options include advancements in diagnostic methodologies, improved understanding of the genetic and molecular bases of the disease, and the development of novel pharmacological agents targeting specific pathways involved in insulin secretion. However, treatments for CHI come with challenges, including potential side effects, such as fluid retention with diazoxide or gastrointestinal symptoms with octreotide, and the risk of incomplete relief from symptoms or hypoglycemia recurrence. Addressing these challenges involves ongoing research into more targeted and less invasive therapeutic strategies, personalized medicine based on genetic profiling, and developing more effective and safer drugs. The advent of artificial pancreas systems that could regulate insulin production and release in real-time offers a transformative approach to managing CHI, providing advanced treatment for the condition.

Please Note: PDF & Excel + Online Access - 1 Year

Table of Contents

192 Pages
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increase in prevalence of congenital hyperinsulinism disease
5.1.1.2. Government initiatives promoting congenital hyperinsulinism diagnosis
5.1.2. Restraints
5.1.2.1. Limited reimbursement available for congenital hyperinsulinism
5.1.3. Opportunities
5.1.3.1. Ongoing R&D for advancing treatment of congenital hyperinsulinism
5.1.3.2. Emerging approval of congenital hyperinsulinism treatments
5.1.4. Challenges
5.1.4.1. Diagnostic challenges and possible complications of the treatment
5.2. Market Segmentation Analysis
5.2.1. Indication Type: Need for a more personalized approach to treat Atypical CHI
5.2.2. End-Users: Need for a diverse range of treatments for congenital hyperinsulinism in hospitals
5.3. Market Disruption Analysis
5.4. Porter’s Five Forces Analysis
5.4.1. Threat of New Entrants
5.4.2. Threat of Substitutes
5.4.3. Bargaining Power of Customers
5.4.4. Bargaining Power of Suppliers
5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis
6. Congenital Hyperinsulinism Treatment Market, by Indication Type
6.1. Introduction
6.2. Atypical Congenital Hyperinsulinism
6.3. Diffuse Congenital Hyperinsulinism
6.4. Focal Congenital Hyperinsulinism
7. Congenital Hyperinsulinism Treatment Market, by Treatment
7.1. Introduction
7.2. Dietary Management
7.3. Drugs
7.4. Surgical Intervention
8. Congenital Hyperinsulinism Treatment Market, by Route of Administration
8.1. Introduction
8.2. Oral
8.3. Parenteral
9. Congenital Hyperinsulinism Treatment Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacies
9.3. Online Pharmacies
9.4. Retail Pharmacies
10. Congenital Hyperinsulinism Treatment Market, by End-Users
10.1. Introduction
10.2. Ambulatory Surgery Centers
10.3. Hospitals
10.4. Specialty Clinics
11. Americas Congenital Hyperinsulinism Treatment Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Congenital Hyperinsulinism Treatment Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Congenital Hyperinsulinism Treatment Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.3.1. C-Path and Congenital Hyperinsulinism International Announce Data Sharing Agreement
14.3.2. Zealand Pharma Submits New Drug Application to US FDA for Dasiglucagon In Congenital Hyperinsulinism
14.3.3. Rhythm Pharmaceuticals Announces Acquisition of Xinvento B.V. and Portfolio of Investigational Therapeutics
14.4. Strategy Analysis & Recommendation
15. Competitive Portfolio
15.1. Key Company Profiles
15.2. Key Product Portfolio
FIGURE 1. CONGENITAL HYPERINSULINISM TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. CONGENITAL HYPERINSULINISM TREATMENT MARKET DYNAMICS
FIGURE 7. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2023 VS 2030 (%)
FIGURE 8. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
FIGURE 10. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 12. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 14. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
FIGURE 16. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 20. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 25. CONGENITAL HYPERINSULINISM TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 26. CONGENITAL HYPERINSULINISM TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us